Contract Manufacturing vs Private Label: How Supplement Brands Should Choose
Brand owners tend to treat “contract manufacturing” as a single thing with a single price. In practice there are three distinct partnership models in the nutraceutical and functional food industry, and they differ on the questions that matter most: who owns the formula, who holds regulatory responsibility, how much you can differentiate, and what you are allowed to change later.
Choosing the wrong model does not usually fail at launch. It typically fails at the point of success — when you want to scale, change a supplier, or sell into a new market and discover that you do not control the thing your brand is built on.
The three models
Private label or white label works by catalogue: you select an existing product, apply your branding, and the manufacturer produces it. The formula stays the manufacturer’s, differentiation is low because the same product may be sold under other brands, and the entry threshold is the lowest of the three — sometimes a share of a production run that is already scheduled.
Contract manufacturing works the other way round: the manufacturer produces to a formula you supply, and what it brings is process capability. The formula is yours if the agreement says so, differentiation is high if the formula is genuinely yours, and the entry threshold is moderate — enough volume to justify a production run.
Custom formulation, sometimes described as OEM or ODM, brings the manufacturer’s R&D team into the development, either developing the formula or co-developing it with you before producing it. Formula ownership here is negotiated, and that is the critical clause; differentiation is high but contingent on those ownership terms, and the entry threshold is moderate to high depending on how much development input is required.
The essential distinction is that private label sells you a product, contract manufacturing sells you capacity, and custom formulation sells you development capability. Each is appropriate to a different stage and strategy, and the cost structures are not comparable.
The five questions that decide the model
1. Who owns the formula when the relationship ends?
This is the clause that determines what your brand is actually worth. In private label, the answer is that the formula was never yours — which is acceptable if the product is genuinely a commodity, and unacceptable if your brand’s entire proposition rests on it.
In contract manufacturing and custom formulation, ownership must be written explicitly. Three provisions matter. The first is formula ownership, stated in writing rather than implied by who paid for development. The second is confidentiality and non-use, so that the manufacturer is prohibited from producing a materially identical formula for another brand. The third is transition rights — your right, on termination, to the documentation needed to have the product made elsewhere, and on what terms.
Without the third provision, ownership of the formula is largely theoretical: you may own it and still be unable to leave.
2. Who is the legal manufacturer of record?
Regulatory responsibility follows the manufacturer of record, and that entity differs by model and by market. For a dietary supplement or functional food, the declaration on the label and the entity answerable for the manufacturing records is a specific organisation, and your compliance obligations depend on whether that is you, the manufacturer, or shared.
Establish before signing who is named as manufacturer on the label in each destination market; who holds the manufacturing records and for how long, and whether you have access to them; who is responsible for regulatory review of claims and labelling in each market; and who notifies whom, and within what period, if a formulation or process changes.
A change control clause is not administrative boilerplate. A manufacturer that changes a raw material source or a process step without notifying you can compromise your label, your stability data and your claims — and the responsibility for the resulting problem will sit with whoever is the manufacturer of record.
3. What volume makes the model viable?
Minimum order quantities differ enormously between the three models, and they are usually expressed in production runs rather than units, because the constraint is the equipment rather than the material. In private label the driver is the existing production schedule, and your order is often a share of a run, which is why the entry threshold is lowest and the manufacturer may already be producing the product. Contract manufacturing requires a full production run of the specified format, so you may need to build inventory or accept a larger first order than the forecast supports. Custom formulation carries a full production run as well, but adds development time to it — so the MOQ constraint arrives with development cost and timeline attached.
Two practical measures: ask what the minimum viable first run is rather than the published MOQ, and ask whether the manufacturer can produce at multiple scales so that launch volume and scale-up volume do not require two different vendors.
4. What capability does the format need?
Manufacturing capability is format-specific, and this is where genuine differentiation between suppliers sits. Powder blends and premixes are judged on blending homogeneity, granulation or agglomeration, moisture and water activity control, and dust management. Capsules turn on filling accuracy and powder flow at speed, plus shell sourcing — including the gelatin or plant-derived question, which carries Halal and Kosher consequences. Tablets depend on compression at commercial speed, uniformity of dose and coating capability. Stick packs and sachets are decided by fill accuracy at high speed, barrier film handling and sealing integrity.
The remaining formats are liquid or heat-formed, and their constraints come from that. Gummies need cooking and depositing control, and they impose a thermal load on heat-sensitive actives, so colour and texture stability has to be demonstrated rather than assumed. Liquids and shots depend on homogenisation, preservation, and thermal processing appropriate to the active.
Two questions separate a capable manufacturer from a hopeful one: “have you produced this format at this dose, and can you show me the process parameters?” and “what is your in-process control plan for the parameter most likely to vary?”
5. Who carries the development risk?
In custom formulation, the development work is the value you are buying — and the risk allocation should be explicit. Does the manufacturer guarantee that the formulation will meet an agreed specification, and what happens if it does not? Who pays for stability testing, and who owns the resulting data? Who owns the analytical method if a new one is developed for your product? And if the project is abandoned at the prototype stage, what does each party keep?
For a brand, the most valuable output of a development project is often the documentation set — specification, method, stability data and process parameters — rather than the physical product. Make ownership of that documentation explicit.
A comparison on the dimensions that matter
On the entry economics, private label carries the lowest upfront cost and the fastest time to market, contract manufacturing sits in the middle on both, and custom formulation is the highest cost and the slowest to market of the three.
Product differentiation and formula control separate the models on what you actually own. Private label offers low differentiation and no formula control at all. Contract manufacturing offers high differentiation, with the formula yours if it is documented. Custom formulation also offers high differentiation, but its formula control is negotiated — which means it has to be clarified rather than assumed.
The next two dimensions show up when the relationship changes. The ability to switch manufacturer later is difficult in practice under private label, good under contract manufacturing provided documentation rights exist, and depends entirely on IP terms under custom formulation. And the exposure if the product succeeds follows the same pattern: under private label, competitors can buy the same product; under contract manufacturing, your exposure is limited to your formula; under custom formulation it is limited subject to exclusivity terms.
As for best suited to: private label fits testing a category, filling a range or reaching the market quickly; contract manufacturing fits established brands with a defined product; and custom formulation fits brands whose proposition is the formulation itself.
A strategy that works well for many brands: use private label to test a category quickly, then migrate your winners to contract or custom manufacturing once the demand is proven. Migrating is far easier if, from the beginning, you have required formula documentation and negotiated transition rights.
Practical due diligence before signing
Certification scope, audit history and testing capability are the first three checks, and they establish what the manufacturer is. Establish which certificates it holds, in whose name, and scoped to which products; obtain the most recent third-party audit report or an equivalent; and determine whether testing is in-house, with a named external laboratory, or both.
Allergen and cross-contact control, the quality agreement and traceability establish how the quality system actually runs. Look for segregation and cleaning validation, particularly at multi-product facilities; insist on a written quality agreement defining specification, testing, deviation handling and notification; and require batch records that link your finished lot to the raw materials used.
Supply continuity and exit terms establish what happens when things change: what occurs if a key raw material becomes unavailable, and who bears that risk; and the notice period, final order rights, and the transition of documentation and tooling.
Frequently Asked Questions
Is private label always a bad idea?
No. It is a rational choice for testing demand, filling out a product range or entering a category quickly. The mistake is using it for a product you intend to build a brand on, and then discovering that the formulation is not yours and cannot be taken with you.
Who owns the formula in a custom formulation project?
Whichever the agreement says — which is exactly why it must be written down. Where the manufacturer’s R&D team does the development, ownership commonly sits with the manufacturer unless it is explicitly assigned or licensed to you. Negotiate this before development starts, not after the product succeeds.
What MOQ should I expect?
Expect it to be expressed as a production run rather than a unit count, and expect it to differ by format. Ask for the minimum viable first run and confirm whether the manufacturer can support you at more than one scale, so growth does not require changing vendors.
How do I protect my formula if I have to switch manufacturers?
Require three things upfront: documented formula ownership, a non-use and confidentiality clause, and transition rights that specify what documentation you receive on termination and in what form. Without the third, the first two are difficult to exercise.
What is the most commonly overlooked clause?
Change notification. A manufacturer that substitutes a raw material or alters a process step without telling you can invalidate your label, your stability data and your claims — and if they are the manufacturer of record, the compliance consequence lands on the label your brand is on.
